Regulatory12/08/2026
Freenome Receives Breakthrough Device Designation
Farallon Capital Management →FDA granted Breakthrough Device designation to Freenome's blood-based lung-cancer screening test.
FDA granted Breakthrough Device designation to Freenome's blood-based lung-cancer screening test.